Brief: Curevac: Positive Phase 2 Interim Data From Covid-19 Vaccine Development Program
05/01/2024 12:02
Jan 5 (Reuters) - Curevac Nv 5CV.DE :
* CUREVAC ANNOUNCES POSITIVE PHASE 2 INTERIM DATA FROM
COVID-19
VACCINE DEVELOPMENT PROGRAM IN COLLABORATION WITH GSK PROVIDING
STRONG VALIDATION OF PROPRIETARY TECHNOLOGY PLATFORM
* HEAD-TO-HEAD COMPARISON WITH LICENSED BIVALENT MRNA-BASED
COMPARATOR VACCINE CONFIRMS COMPETITIVE IMMUNE RESPONSES AT
LOWER DOSES AND FAVORABLE TOLERABILITY PROFILE
* MONOVALENT MRNA VACCINE CANDIDATE, CV0601, ENCODING
OMICRON
BA.4-5 VARIANT AND BIVALENT CANDIDATE, CV0701, ENCODING OMICRON
BA.4-5 VARIANT AS WELL AS ORIGINAL SARS-COV-2 VIRUS,
SUCCESSFULLY BOOSTED ANTIBODY TITERS AND WERE GENERALLY WELL
TOLERATED ACROSS ALL TESTED DOSE LEVELS
Source text for Eikon: ID:nEQ1fxjRha
Further company coverage: 5CV.DE
(Reporting by Berlin Newsroom)
((berlin.newsroom@thomsonreuters.com;))
Recent news on CureVac NV
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Biontech Closes Acquisition Of CureVac
Brief: BioNTech Says CureVac Shareholders Are Advised To Tender Their Shares By 6:00 P.M. Eastern Time On Tuesday, December 2, 2025
Brief: Curevac Reaffirms Its Expected Cash Runway Into 2028